GHP Family Pharmacy Customer Service
100 N. Academy Ave.
Danville, PA 17822
Tel. • 855•552•6028 PA Relay 711 GeisingerHealthPlan.com

Geisinger

HYPOGLYCEMICS, INCRETIN ENHANCERS (DPP-4 inhibitors) PRIOR AUTHORIZATION FORM

(form effective 01/05/2021)

Prior authorization guidelines for Hypoglycemics, Incretin Mimetics/Enhancers and Quantity Limits/Daily Dose Limits are available on Geisinger Health Plan's website at https://healthplan.geisinger.org/pharmacy/pharmacy.aspx?strip=true&style=OneGeisinger

☐ New request ☐ Renewal request	Total # pages: _____	Prescriber name:	
Name of office contact:		Specialty:	
Phone number of office contact:		NPI:	State license #:
Facility contact/phone:		Street address:	
Beneficiary name:		Suite #:	City/state/zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in each class

Drug requested:	Strength:
Dose/directions	Quantity: / Refills:
Diagnosis (*Submit documentation*):	Dx code (*required*):
Requests for a NON-PREFERRED medication: Please list the preferred Hypoglycemics, Incretin Enhancers (DPP-4 Inhibitors) that the beneficiary has had a therapeutic failure, contraindication, or intolerance to. *Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in each class*	*Submit all supporting documentation of preferred agents tried and treatment outcomes, including contraindications or intolerances.*
Will the beneficiary be using the requested DPP-4 inhibitor in addition to a GLP-1 receptor agonist (e.g., Bydureon, Ozempic, Rybelsus, Trulicity, Victoza, etc.), Symlin, or another DPP-4 inhibitor?	☐ Yes – *Submit medical literature supporting the concomitant use of these medications* ☐ No
Did the beneficiary have a mental health evaluation?	☐ Yes ☐ No *Submit documentation of evaluation.*

Check all of the following that apply to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.

☐ Has a history of trial and failure of maximum tolerated doses of metformin as evidenced by HbA1c results. Provide HbA1c value: _____
☐ Has a contraindication or intolerance to metformin
☐ Requires initial dual therapy with metformin based on HbA1c as defined by current ADA and/or AACE/ACE guidelines.
Provide HbA1c value:_____
☐ Has the following comorbidities:
- ☐ cardiovascular disease
- ☐ at least 2 risk factors for cardiovascular disease. Please provide the member's risk factors for CVD: _____
- ☐ heart failure
- ☐ chronic kidney disease

Please submit to PromptPA https://ghp.promptpa.com OR fax to Geisinger Health Plan at 570-271-5610 the completed form with required clinical documentation.

Prescriber Signature:	Date: